Hypera S.A. (BVMF:HYPE3)

Market Cap	12.35B
Revenue (ttm)	7.78B
Net Income (ttm)	1.57B
Shares Out	632.68M
EPS (ttm)	2.46
PE Ratio	7.93
Forward PE	14.90
Dividend	0.68 (3.40%)
Ex-Dividend Date	n/a

Volume	2,421,800
Average Volume	4,085,865
Open	20.00
Previous Close	20.01
Day's Range	19.40 - 20.10
52-Week Range	16.62 - 34.95
Beta	0.45
RSI	58.38
Earnings Date	Feb 21, 2025

About Hypera

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 10,301
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: HYPE3

Financial Performance

In 2023, Hypera's revenue was 7.91 billion, an increase of 4.88% compared to the previous year's 7.55 billion. Earnings were 1.65 billion, a decrease of -2.87%.